CD8A and neoplasm: Our study revealed that after neoadjuvant therapy, ALK-positive NSCLC transitions from an immunologically “hot” tumor to a “cold” tumor with decreased infiltration of CD8+ cells and macrophages, as well as a lower M1/M2 macrophage ratio (Figures 3, 4).